Leverkusen, July 24, 2023 — The Bayer Group changed its full-year outlook for 2023 downward on Monday, primarily due to a substantial additional decrease in sales of glyphosate-based items.
For full-year 2023, Bayer now expects sales of in between 48.5 billion and 49.5 billion euros on a currency-adjusted basis, i.e. based upon the typical month-to-month currency exchange rate in 2022 (previous outlook: 51 billion to 52 billion euros). EBITDA before unique products is now anticipated to be in the series of 11.3 billion and 11.8 billion euros in 2023 on a currency-adjusted basis (previous outlook: 12.5 billion to 13.0 billion euros). The business likewise changed its projection for core revenues per share to in between 6.20 and 6.40 euros on a currency-adjusted basis (previous outlook: 7.20 to 7.40 euros) and totally free capital to roughly absolutely no euros (previous outlook: roughly 3.0 billion euros).
For the 2nd quarter, audited figures are not yet readily available. Sales are anticipated to come in at roughly 11.0 billion euros. EBITDA before unique products is anticipated to total up to around 2.5 billion euros. Bayer expects core profits per share of around 1.20 euros and complimentary capital of roughly minus 0.5 billion euros (all quarterly figures based upon currency exchange rate since June 30, 2023).
When interacting its very first quarter outcomes, Bayer currently assisted towards the lower end of its Group sales and profits projection for this year. More cost decreases and lower volumes due to funnel de-stocking, particularly for glyphosate-based items, in addition to unfavorable climate condition have actually increased pressure. Based upon the awaited market advancement, in specific with regard to the glyphosate organization, Bayer likewise anticipates to tape-record a goodwill problems of roughly 2.5 billion euros. This will lead to unfavorable Group earnings of around 2 billion euros for the 2nd quarter of 2023.
Bayer will launch its comprehensive outcomes for the 2nd quarter on August 8, 2023.
Discover more details at www.bayer.com
Follow us on twitter.com/bayer
Positive Statements
This release might include positive declarations based upon existing presumptions and projections made by Bayer management. Numerous recognized and unidentified dangers, unpredictabilities and other elements might cause product distinctions in between the real future outcomes, monetary scenario, advancement or efficiency of the business and the price quotes offered here. These elements consist of those gone over in Bayer’s public reports which are readily available on the Bayer site at www.bayer.comThe business presumes no liability whatsoever to upgrade these positive declarations or to adhere them to future occasions or advancements.